Stoke Therapeutics, Inc.
Financials
Valuation Metrics
Stoke Therapeutics, Inc.'s Market Cap is $1.71B. At end of 2025 it was $1.85B. Ranked #2092 of 3,118 in US market (top 67%), #801 of 1,474 on NASDAQ (top 54%), #146 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 55%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.71B | US#2,092/3,118 Sec#146/265 |
| Revenue | $28M | US#2,777/3,118 Sec#157/265 |
| Net Income | $-208M | US—/3,118 Sec—/265 |
| Total Assets | $394M | US#2,839/3,118 Sec#188/265 |
| Net Assets | $346M | US#2,448/3,118 Sec#149/265 |
| Employees | 170 | US#2,508/3,118 Sec#133/265 |
| Value | ||
| P/B | 4.94x | US#2,211/3,118 Sec#140/265 |
| P/S | 62.00x | US#2,930/3,118 Sec#174/265 |
| FCF Yield | -10.58% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -60.17% | US#2,710/3,118 Sec#173/265 |
| ROA | -52.77% | US#2,992/3,118 Sec#220/265 |
| Op. Margin | -810.95% | US#2,798/3,118 Sec#162/265 |
| Revenue Growth | -86.22% | US#2,717/3,118 Sec#175/265 |
| Earnings Growth | -496.12% | US#1,975/3,118 Sec#65/265 |
| Financial Health | ||
| Debt Ratio | 14.01% | US#158/3,118 Sec#64/265 |
| Total Debt | $3M | US#2,931/3,118 Sec#229/265 |
| FCF | $-181M | US#2,757/3,118 Sec#201/265 |
| Cash | $110M | US#2,171/3,118 Sec#167/265 |
| Current Ratio | 7.69x | US#323/3,118 Sec#100/265 |
| Performance | ||
| 1Y Return | -11.90% | US#2,337/3,118 Sec#184/265 |
| 1M Return | 3.30% | US#1,655/3,118 Sec#103/265 |
| From 52W High | -34.20% | US#2,141/3,118 Sec#144/265 |
| 1Y MDD | -41.33% | US#1,989/3,118 Sec#126/265 |
| Trading | ||
| Volume | 1,263,935 shares | US#1,139/3,118 Sec#103/265 |
| Trading Value | $33M | US#1,450/3,118 Sec#98/265 |
| Per Share | ||
| EPS | $-3.22 | US—/3,118 Sec—/265 |
| BPS | $5.36 | US#2,249/3,118 Sec#123/265 |
Company Info
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.